Literature DB >> 15385196

Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies.

Victor L Perez1, George N Papaliodis, David Chu, Fahd Anzaar, William Christen, C Stephen Foster.   

Abstract

INTRODUCTION: Although the exact mechanisms that lead to uveitis are not entirely known, the role of cytokines in the pathogenesis of this disease has been shown to be important. Prior studies described the presence of an array of cytokines in the intraocular fluid of patients with uveitis. Review of these studies indicate that Interleukin-6 (IL-6) is present, and animal data suggest the important role of IL-6 in the regulation of ophthalmologic immune responses.
PURPOSE: We investigated whether IL-6, TNF-alpha, IL-1 alpha, beta, IL-2 are present in the vitreous of patients with active intermediate and posterior uveitis.
METHODS: Vitreous specimens were collected from 23 eyes of patients with active intermediate and posterior uveitis who underwent diagnostic or therapeutic vitrectomies. TNF-alpha, IL-1 alpha and beta, IL-2 and IL-6 were measured by enzyme-linked immunosorbent assay. Eight vitreous fluid samples from eye bank eyes were used as control.
RESULTS: IL-6 was higher in the vitreous of patients with uveitis compared to control samples (p = 0.0119). No TNF-alpha, IL-2, IL1-alpha or beta was detected. The levels of IL-6 did not correlate with a specific clinical diagnosis, but patients with pars planitis and panuveitis had the highest levels (p = 0.58)
CONCLUSIONS: IL-6 is elevated in the vitreous of patients with active intermediate and posterior uveitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385196     DOI: 10.1080/092739490500282

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  33 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

2.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

Review 3.  IL-6 blockade in the management of non-infectious uveitis.

Authors:  Giuseppe Lopalco; Claudia Fabiani; Jurgen Sota; Orso Maria Lucherini; Gian Marco Tosi; Bruno Frediani; Florenzo Iannone; Mauro Galeazzi; Rossella Franceschini; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-05-20       Impact factor: 2.980

Review 4.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

5.  Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis.

Authors:  Alejandra de-la-Torre; Alexander W Pfaff; Michael E Grigg; Odile Villard; Ermanno Candolfi; Jorge E Gomez-Marin
Journal:  Cytokine       Date:  2014-04-16       Impact factor: 3.861

Review 6.  Cytokines in autoimmune uveitis.

Authors:  Reiko Horai; Rachel R Caspi
Journal:  J Interferon Cytokine Res       Date:  2011-07-25       Impact factor: 2.607

Review 7.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

Review 8.  Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.

Authors:  Yael Sharon; Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

9.  Remission of Intermediate Uveitis: Incidence and Predictive Factors.

Authors:  John H Kempen; Dina Y Gewaily; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; H Nida Sen; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Abhishek Payal; Tonetta D Fitzgerald
Journal:  Am J Ophthalmol       Date:  2016-01-06       Impact factor: 5.258

10.  Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells.

Authors:  Chris Or; Jing Cui; Joanne Matsubara; Farzin Forooghian
Journal:  Br J Ophthalmol       Date:  2013-06-13       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.